Low-Dose Naltrexon (LDN) – Forschung

Effect of low-dose naltrexone for long COVID: a systematic review and meta-analysis.

Byambasuren O, Atkins T, Baptista S, Glasziou P, Chakraborty S · BMJ Open (2026)

Low dose naltrexone for induction of remission in Crohn's disease.

Parker CE, Nguyen TM, Segal D, MacDonald JK, Chande N · Cochrane Database Syst Rev (2018)

Low Dose Naltrexone In The Management Of Chronic Pain Syndrome: A Meta-Analysis Of Randomized Controlled Clinical Trials.

Hegde NC, Mishra A, V D, Maiti R, Hota D, Srinivasan A · Curr Pain Headache Rep (2025)

Efficacy of Low-Dose Naltrexone in Treating Patients with Fibromyalgia: systematic Review and Meta-Analysis.

Ologunowa A, Otoo MN, Caffrey AR, Buchanan A, Eze UJ, Vyas A · J Pain Palliat Care Pharmacother (2025)

Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review.

Kim PS, Fishman MA · Curr Pain Headache Rep (2020)

Naltrexone's Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures.

Liubchenko K, Kordbacheh K, Khajehdehi N, Visnjevac T, Ma F, Khan JS · Adv Ther (2021)

Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review.

Ekelem C, Juhasz M, Khera P, Mesinkovska NA · JAMA Dermatol (2019)

Is low-dose naltrexone effective in chronic pain management?

Radi R, Huang H, Rivera J, Lyon C, DeSanto K · J Fam Pract (2023)

Low-Dose Naltrexone for the Treatment of Fibromyalgia: Investigation of Dose-Response Relationships.

Bruun-Plesner K, Blichfeldt-Eckhardt MR, Vaegter HB, Lauridsen JT, Amris K, Toft P · Pain Med (2020)

Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study.

Bouvard MP, Leboyer M, Launay JM, Recasens C, Plumet MH, Waller-Perotte D · Psychiatry Res (1995)

The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.

Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B · Mult Scler (2010)

The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled clinical trial.

Lajevardi V, Salarvand F, Ghiasi M, Nasimi M, Taraz M · J Dermatolog Treat (2022)

Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: A randomized, double-blind, active-control, crossover clinical trial.

Srinivasan A, Dutta P, Bansal D, Chakrabarti A, Bhansali AK, Hota D · J Diabetes (2021)

Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study.

Smith JP, Field D, Bingaman SI, Evans R, Mauger DT · J Clin Gastroenterol (2013)

Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis.

Cree BA, Kornyeyeva E, Goodin DS · Ann Neurol (2010)

Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial.

Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO · Dig Dis Sci (2011)

Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants.

Mischoulon D, Hylek L, Yeung AS, Clain AJ, Baer L, Cusin C · J Affect Disord (2017)

Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.

Younger J, Noor N, McCue R, Mackey S · Arthritis Rheum (2013)

Efficacy and Safety of Low Dose Naltrexone for Chronic Pain

Einfach gesagt: LDN was associated with a statistically significant reduction in PEG in adult chronic pain patients, however the clinical significance is unclear as over 75% of patients discontinued LDN due to lack of benefit.

N Irwin M, A Cooke D, Berland D, D Marshall V, A Smith M. · Journal of pain & palliative care pharmacotherapy (2024)

Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia

Naik H, Cooke E, Boulter T, Dyer R, Bone JN, Tsai M, Cristobal J, McKay RJ, Song X, Nacul L. · BMJ open (2024)